Inventor · disambiguated record
Merouane Bencherif
Also filed as: BENCHERIF MEROUANE
33 granted patents·17 pending applications·1,429 citations·filing 1994–2019
98Inventor score
Files withTARGACEPT INC22BENCHERIF MEROUANE7ATACAMA THERAPEUTICS INC3ATTENUA INC1CALDWELL WILLIAM S1
Top patents by PatentIndex Score
50 records- 0198US5861423APharmaceutical compositions incorporating aryl substituted olefinic amine compoundsFiled 1997·Granted Jan 19, 1999·119 cites·12 claims
- 0298US5583140APharmaceutical compositions for the treatment of central nervous system disordersFiled 1995·Granted Dec 10, 1996·181 cites·15 claims
- 0395US5604231APharmaceutical compositions for prevention and treatment of ulcerative colitisFiled 1995·Granted Feb 18, 1997·329 cites·21 claims
- 0493US6166048APharmaceutical compositions for inhibition of cytokine production and secretionTARGACEPT INC·Filed 1999·Granted Dec 26, 2000·105 cites·19 claims
- 0593US5824692APharmaceutical compositions for prevention and treatment of central nervous system disordersFiled 1995·Granted Oct 20, 1998·67 cites·26 claims
- 0692US7214686B2Pharmaceutical compositions and methods for effecting dopamine releaseTARGACEPT INC·Filed 2003·Granted May 8, 2007·28 cites·2 claims
- 0792US6232316B1Methods for treatment of CNS disordersTARGACEPT INC·Filed 1998·Granted May 15, 2001·48 cites·9 claims
- 0891US6274606B1Methods of treating central nervous system disorders with aryl substituted olefinic amine compoundsTARGACEPT INC·Filed 1998·Granted Aug 14, 2001·46 cites·16 claims
- 0991US5811442APharmaceutical compositions for the treatment of conditions associated with decreased blood flowFiled 1997·Granted Sep 22, 1998·109 cites·46 claims
- 1089US6489349B1Pharmaceutical compositions for inhibition of cytokine production and secretionTARGACEPT INC·Filed 2000·Granted Dec 3, 2002·31 cites·43 claims
- 1189US5952339APharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter releaseFiled 1998·Granted Sep 14, 1999·96 cites·34 claims
- 1286US5885998AMethods for prevention and treatment of attention deficit disorderFiled 1998·Granted Mar 23, 1999·28 cites·18 claims
- 1383US6979695B2Compounds capable of activating cholinergic receptorsTARGACEPT INC·Filed 2002·Granted Dec 27, 2005·13 cites·37 claims
- 1482US7067261B2Methods and compositions for treatment of central nervous system disordersMED COLLEGE GEORGIA RES INST·Filed 2002·Granted Jun 27, 2006·23 cites·11 claims
- 1581US5510355ADepolarizing skeletal muscle relaxantsFiled 1994·Granted Apr 23, 1996·51 cites·14 claims
- 1680US6525065B1Pharmaceutical compositions and methods for effecting dopamine releaseTARGACEPT INC·Filed 1997·Granted Feb 25, 2003·24 cites·11 claims
- 1779US10080726B2Method for treating hyperhidrosis with dexmecamylamineATACAMA THERAPEUTICS INC·Filed 2015·Granted Sep 25, 2018·2 cites·19 claims
- 1879US8901151B2Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamideTARGACEPT INC·Filed 2013·Granted Dec 2, 2014·3 cites·1 claims
- 1979US8901177B2Method of treating bladder disordersTARGACEPT INC·Filed 2013·Granted Dec 2, 2014·3 cites·7 claims
- 2079US7045538B2Compounds capable of activating cholinergic receptorsTARGACEPT INC·Filed 2004·Granted May 16, 2006·8 cites·9 claims
- 2177US8476296B2Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamideBENCHERIF MEROUANE·Filed 2010·Granted Jul 2, 2013·4 cites·15 claims
- 2276US10507190B2Method for treating hyperhidrosis with dexmecamylamineATACAMA THERAPEUTICS INC·Filed 2018·Granted Dec 17, 2019·1 cites·18 claims
- 2376US6218383B1Pharmaceutical compositions for the prevention and treatment of central nervous system disordersTARGACEPT INC·Filed 1998·Granted Apr 17, 2001·37 cites·10 claims
- 2473US5731314APharamceutical compositions for prevention and treatment of tourette's syndromeFiled 1995·Granted Mar 24, 1998·29 cites·4 claims
- 2571US9173876B2Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamideTARGACEPT INC·Filed 2014·Granted Nov 3, 2015·1 cites·1 claims
- 2669US8846715B2(2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereofTARGACEPT INC·Filed 2013·Granted Sep 30, 2014·1 cites·3 claims
- 2768US5922723APharmaceutical compositions for prevention and treatment of central nervous system disordersFiled 1996·Granted Jul 13, 1999·9 cites·14 claims
- 2868US2010121061A1Compounds capable of activating cholinergic receptorsTARGACEPT INC·Filed 2009·Application pending·0 cites
- 2967US8541446B2(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereofBENCHERIF MEROUANE·Filed 2011·Granted Sep 24, 2013·1 cites·3 claims
- 3064US11166922B2Method for treating hyperhidrosis with dexmecamylamineATACAMA THERAPEUTICS INC·Filed 2019·Granted Nov 9, 2021·0 cites·18 claims
- 3161US2009239901A1Method and compositions for treatment of cerebral malariaBENCHERIF MEROUANE·Filed 2009·Application pending·0 cites
- 3260US2015045386A1(2s,3r)-n-2-3-pyridinylmethyl-1-azabicyclo 2.2.2 oct-3-yl benzofuran-2-carboxamide, novel salt forms, and methods of use thereofTARGACEPT INC·Filed 2014·Application pending·0 cites
- 3359US6100269APharmaceutical compositions for prevention and treatment of central nervous system disordersFiled 1999·Granted Aug 8, 2000·5 cites·13 claims
- 3459US2011098312A1Methods for preventing the development of retinopathy by the oral administration of nnr ligandsTARGACEPT INC·Filed 2009·Application pending·0 cites
- 3558US2006293289A1Compounds Capable of Activating Cholinergic ReceptorsCALDWELL WILLIAM S·Filed 2006·Application pending·0 cites
- 3656US6107298AMethods for prevention and treatment of Tourette's syndrome and schizophreniaFiled 1999·Granted Aug 22, 2000·13 cites·4 claims
- 3756US5559124ADepolarizing skeletal muscle relaxantsFiled 1995·Granted Sep 24, 1996·14 cites·8 claims
- 3856US2007185086A1Pharmaceutical Compositions and Methods for Effecting Dopamine ReleaseBENCHERIF MEROUANE·Filed 2007·Application pending·0 cites
- 3955US2011262407A1Treatment with alpha7 selective ligandsTARGACEPT INC·Filed 2009·Application pending·0 cites
- 4049US7550293B2Chimeric nicotinic receptor subunitsTARGACEPT INC·Filed 2005·Granted Jun 23, 2009·0 cites·6 claims
- 4149US2010247617A1Transdermal Administration Of (2S)-(4E)-N-Methyl-5-(3-(5-Isopropoxypyridin)yl)-4-Penten-2-AmineTARGACEPT INC·Filed 2008·Application pending·0 cites
- 4247US2014234270A1Treatment wth alphat selective ligandsTARGACEPT INC·Filed 2014·Application pending·0 cites
- 4347US2010028447A1Intranasal, Buccal, And Sublingual Administration Of Metanicotine AnalogsTARGACEPT INC·Filed 2008·Application pending·0 cites
- 4447US2011059947A1Alpha 7 nicotinic agonists and antipsychoticsTARGACEPT INC·Filed 2009·Application pending·0 cites
- 4547US2017119746A1Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamideATTENUA INC·Filed 2015·Application pending·0 cites
- 4644US2006160835A1Methods and compositions for treatment of central nervous system disordersBENCHERIF MEROUANE·Filed 2006·Application pending·0 cites
- 4738US2009068642A1Composition and pharmacology of novel alpha6-containing nicotinic acetylcholine receptorsBENCHERIF MEROUANE·Filed 2006·Application pending·0 cites
- 4832US2012157477A1Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligandsJORDAN KRISTEN G·Filed 2010·Application pending·0 cites
- 4930US2014024638A1Treatment of cognitive dysfunction in schizophreniaBENCHERIF MEROUANE·Filed 2012·Application pending·0 cites
- 5025US2013237550A1Arylvinylazacycloalkane compounds for constipationTOLER STEVEN M·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Merouane Bencherif files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →